Physician profile
Chad Savage
NPI 1912977869
$3,197.39
in general payments reported to CMS, 2019-2025
16 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $66.46 · 2021: $341 · 2022: $573 · 2023: $763 · 2024: $513 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.71 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,424.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $599.96 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $227.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $225.26 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $218.00 | 2019-2024 | Ubrelvy |
| Pfizer INC. | $130.01 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $63.37 | 2022 | |
| Glaxosmithkline, LLC. | $55.28 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $50.57 | 2021-2024 | |
| Edwards Lifesciences Corporation | $43.06 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Teva Pharmaceuticals USA, INC. | $38.14 | 2022 | |
| Paratek Pharmaceuticals, INC. | $37.15 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $36.25 | 2024 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.80 | 2023 | |
| Medline Industries Lp | $15.57 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $14.64 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.